Takudzwa Mkorombindo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takudzwa Mkorombindo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Ron Balkissoon
Denver, Colorado
4 shared publicationsMark T. Dransfield
Lung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
3 shared publications- Mark Thomas Dransfield
Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294
3 shared publications - Steven R. Duncan
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
2 shared publications Adnan Custovic
National Heart and Lung Institute, Imperial College London, London, United Kingdom
1 shared publication- Alok Bhatt
Department of Internal Medicine, University of Louisville, 550 S. Jackson Street, ACB 3rd Floor, Louisville, KY 40202, USA
1 shared publication
Latest Publications
- Open Access
- 15 February 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (4) , 378-380
The Air We Breathe: Respiratory Impact of Indoor Air Quality in Chronic Obstructive Pulmonary Disease
- 15 February 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (4) , 378-380
Open AccessThe Air We Breathe: Respiratory Impact of Indoor Air Quality in Chronic Obstructive Pulmonary Disease
- 1 January 2022
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 9 (2) , 285-297
Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease
Mkorombindo T, Balkissoon R. Journal club:biologics and potential for immune modulation in chronic obstructive lung disease.
- 1 January 2022
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 9 (2) , 285-297
Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease
Mkorombindo T, Balkissoon R. Journal club:biologics and potential for immune modulation in chronic obstructive lung disease.
- 1 January 2022
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 9 (1) , 103-110
Journal Club-Respiratory Impairment With A Preserved Spirometric Ratio
Mkorombindo T, Balkisson R. Journal club: respiratory impairment with a preserved spirometric ratio.
- 1 January 2022
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 9 (1) , 103-110
Journal Club-Respiratory Impairment With A Preserved Spirometric Ratio
Mkorombindo T, Balkisson R. Journal club: respiratory impairment with a preserved spirometric ratio.
- 13 December 2021
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 28 (2) , 109-114
Pre-chronic obstructive pulmonary disease: a pathophysiologic process or an opinion term?
Purpose of review: Current guidelines does not include current or former smokers who do not have spirometric airflow limitation in their diagnostic or therapeutic algorithms for chronic obstructive pulmonary disease (COPD). The purpose of this review is to outline the burden of respiratory morbidity in this population and to discuss the potential utility of their classification as pre-COPD. Recent findings: It is increasingly clear that patients with a history of exposure to cigarette smoke or other environmental pollutants may have substantial lung pathology and respiratory impairment even in the absence of airflow limitation, as detected by spirometry. Not all of these patients will develop airflow limitation, but many will have considerable respiratory morbidity and a comparable prognosis to those with classical, spirometrically defined COPD. The use of the term pre-COPD may allow for the identification of these individuals in order to target preventive and earlier therapeutic strategies. Summary: Spirometry is not adequately sensitive to identify many current and former smokers and other exposed populations with significant lung pathology and respiratory symptoms. Though the pathologic processes present in these patients differ, the earlier identification of this pre-COPD population may foster the development of more effective and disease-modifying treatments.
- 13 December 2021
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 28 (2) , 109-114
Pre-chronic obstructive pulmonary disease: a pathophysiologic process or an opinion term?
Purpose of review: Current guidelines does not include current or former smokers who do not have spirometric airflow limitation in their diagnostic or therapeutic algorithms for chronic obstructive pulmonary disease (COPD). The purpose of this review is to outline the burden of respiratory morbidity in this population and to discuss the potential utility of their classification as pre-COPD. Recent findings: It is increasingly clear that patients with a history of exposure to cigarette smoke or other environmental pollutants may have substantial lung pathology and respiratory impairment even in the absence of airflow limitation, as detected by spirometry. Not all of these patients will develop airflow limitation, but many will have considerable respiratory morbidity and a comparable prognosis to those with classical, spirometrically defined COPD. The use of the term pre-COPD may allow for the identification of these individuals in order to target preventive and earlier therapeutic strategies. Summary: Spirometry is not adequately sensitive to identify many current and former smokers and other exposed populations with significant lung pathology and respiratory symptoms. Though the pathologic processes present in these patients differ, the earlier identification of this pre-COPD population may foster the development of more effective and disease-modifying treatments.
- Open Access
- 23 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0260345
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations
Background: No medical treatment has proven efficacy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF), and this syndrome has a very high mortality. Based on data indicating humoral autoimmune processes are involved in IPF pathogenesis, we treated AE-IPF patients with an autoantibody reduction regimen of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin. This study aimed to identify clinical and autoantibody determinants associated with survival after autoantibody reduction in AE-IPF. Methods: Twenty-four(24) AE-IPF patients received the autoantibody reduction regimen. Plasma anti-epithelial autoantibody titers were determined by HEp-2 indirect immunofluorescence assays in 22 patients. Results: Mean age of the patients was 70 + 7 years old, and 70% were male. Beneficial clinical responses that occurred early during therapy were a favorable prognostic indicator: supplemental O2 flows needed to maintain resting SaO2>92% significantly decreased and/or walk distances increased among all 10 patients who survived for at least one year. Plasma anti-HEp-2 autoantibody titers were ~-three-fold greater in survivors compared to non-survivors (p1:160 were present in 75% of the evaluable one-year survivors, compared to 29% of non-survivors, and 10 of 12 patients (83%) with anti-HEP-2 titers <1:160 died during the observation period (Hazard Ratio = 3.3, 95% Confidence Interval = 1.02–10.6, p = 0.047). Conclusions: Autoantibody reduction therapy is associated with rapid reduction of supplemental oxygen requirements and/or improved ability to ambulate in many AE-IPF patients. Facile anti-epithelial autoantibody assays may help identify those most likely to benefit from these treatments.
- 23 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0260345
Open AccessCorrelates of survival after autoantibody reduction therapy for acute IPF exacerbations
Background: No medical treatment has proven efficacy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF), and this syndrome has a very high mortality. Based on data indicating humoral autoimmune processes are involved in IPF pathogenesis, we treated AE-IPF patients with an autoantibody reduction regimen of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin. This study aimed to identify clinical and autoantibody determinants associated with survival after autoantibody reduction in AE-IPF. Methods: Twenty-four(24) AE-IPF patients received the autoantibody reduction regimen. Plasma anti-epithelial autoantibody titers were determined by HEp-2 indirect immunofluorescence assays in 22 patients. Results: Mean age of the patients was 70 + 7 years old, and 70% were male. Beneficial clinical responses that occurred early during therapy were a favorable prognostic indicator: supplemental O2 flows needed to maintain resting SaO2>92% significantly decreased and/or walk distances increased among all 10 patients who survived for at least one year. Plasma anti-HEp-2 autoantibody titers were ~-three-fold greater in survivors compared to non-survivors (p1:160 were present in 75% of the evaluable one-year survivors, compared to 29% of non-survivors, and 10 of 12 patients (83%) with anti-HEP-2 titers <1:160 died during the observation period (Hazard Ratio = 3.3, 95% Confidence Interval = 1.02–10.6, p = 0.047). Conclusions: Autoantibody reduction therapy is associated with rapid reduction of supplemental oxygen requirements and/or improved ability to ambulate in many AE-IPF patients. Facile anti-epithelial autoantibody assays may help identify those most likely to benefit from these treatments.
- Open Access
- 8 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (19)
HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk
A role for hereditary influences in the susceptibility for chronic obstructive pulmonary disease (COPD) is widely recognized. Cytotoxic lymphocytes are implicated in COPD pathogenesis, and functions of these leukocytes are modulated by interactions between their killer cell Ig-like receptors (KIR) and human leukocyte antigen–Class I (HLA–Class I) molecules on target cells. We hypothesized HLA–Class I and KIR inheritance affect risks for COPD. HLA–Class I alleles and KIR genotypes were defined by candidate gene analyses in multiple cohorts of patients with COPD (total n = 392) and control smokers with normal spirometry (total n = 342). Compared with controls, patients with COPD had overrepresentations of HLA-C*07 and activating KIR2DS1 , with underrepresentations of HLA-C*12 . Particular HLA-KIR permutations were synergistic; e.g., the presence of HLA-C*07 + KIR2DS1 + HLA-C12 null versus HLAC*07 null + KIR2DS1 null + HLA-C12 was associated with COPD, especially among HLA-C1 allotype homozygotes. Cytotoxicity of COPD lymphocytes was more enhanced by KIR stimulation than those of controls and was correlated with lung function. These data show HLA-C and KIR polymorphisms strongly influence COPD susceptibility and highlight the importance of lymphocyte-mediated cytotoxicity in COPD pathogenesis. Findings here also indicate that HLA-KIR typing could stratify at-risk patients and raise possibilities that HLA-KIR axis modulation may have therapeutic potential.
- 8 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (19)
Open AccessHLA-C and KIR permutations influence chronic obstructive pulmonary disease risk
A role for hereditary influences in the susceptibility for chronic obstructive pulmonary disease (COPD) is widely recognized. Cytotoxic lymphocytes are implicated in COPD pathogenesis, and functions of these leukocytes are modulated by interactions between their killer cell Ig-like receptors (KIR) and human leukocyte antigen–Class I (HLA–Class I) molecules on target cells. We hypothesized HLA–Class I and KIR inheritance affect risks for COPD. HLA–Class I alleles and KIR genotypes were defined by candidate gene analyses in multiple cohorts of patients with COPD (total n = 392) and control smokers with normal spirometry (total n = 342). Compared with controls, patients with COPD had overrepresentations of HLA-C*07 and activating KIR2DS1 , with underrepresentations of HLA-C*12 . Particular HLA-KIR permutations were synergistic; e.g., the presence of HLA-C*07 + KIR2DS1 + HLA-C12 null versus HLAC*07 null + KIR2DS1 null + HLA-C12 was associated with COPD, especially among HLA-C1 allotype homozygotes. Cytotoxicity of COPD lymphocytes was more enhanced by KIR stimulation than those of controls and was correlated with lung function. These data show HLA-C and KIR polymorphisms strongly influence COPD susceptibility and highlight the importance of lymphocyte-mediated cytotoxicity in COPD pathogenesis. Findings here also indicate that HLA-KIR typing could stratify at-risk patients and raise possibilities that HLA-KIR axis modulation may have therapeutic potential.
- Open Access
- 11 January 2021
- Published by Wiley in Respirology
- Vol. 26 (4) , 290-291
COPD: COagulation‐associated Pulmonary Disease?
- 11 January 2021
- Published by Wiley in Respirology
- Vol. 26 (4) , 290-291
Open AccessCOPD: COagulation‐associated Pulmonary Disease?
- 1 January 2021
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 8 (4) , 580-588
Journal Club: Non-invasive Mechanical Ventilation in Stable COPD
Mkorombindo T, Balkissoon R. Journal club: non-invasive mechanical ventilation in stable COPD.
- 1 January 2021
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 8 (4) , 580-588
Journal Club: Non-invasive Mechanical Ventilation in Stable COPD
Mkorombindo T, Balkissoon R. Journal club: non-invasive mechanical ventilation in stable COPD.
- 1 January 2021
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 8 (3) , 408-413
Journal Club-Respiratory Impact of Wildfire Smoke
Mkorombindo T. Journal Club: respiratory impact of wildfire smoke.
- 1 January 2021
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 8 (3) , 408-413
Journal Club-Respiratory Impact of Wildfire Smoke
Mkorombindo T. Journal Club: respiratory impact of wildfire smoke.
- Open Access
- 22 October 2020
- Published by Springer Nature in Cureus
- Vol. 12 (10)
Recurrent Pneumonia? A Case of Availability Bias and Anchoring
Invasive mucinous adenocarcinoma is a multi-centric adenocarcinoma that accounts for less than 5% of all lung cancer diagnoses. The most common presenting symptoms (cough, sputum production, and chest pain) in conjunction with its radiographic findings (patchy, multi-lobar infiltrates) make invasive mucinous adenocarcinoma challenging to distinguish from both infectious and inflammatory pneumonia. However, due to its aggressive nature, invasive mucinous adenocarcinoma should be considered if a presumed case of pneumonia lacks symptoms of infection (e.g., fever, leukocytosis) and/or does not respond to antibiotics. We report the case of a 75-year-old male who was admitted in the setting of a presumed case of recurrent pneumonia, which had failed to respond to prior antibiotic therapy. Further workup, including trans-bronchial biopsy, confirmed mucinous adenocarcinoma with a lepidic pattern. This case highlights the importance of establishing a broad differential in the setting of unresolved pneumonia following appropriate antibiotic coverage.
- 22 October 2020
- Published by Springer Nature in Cureus
- Vol. 12 (10)
Open AccessRecurrent Pneumonia? A Case of Availability Bias and Anchoring
Invasive mucinous adenocarcinoma is a multi-centric adenocarcinoma that accounts for less than 5% of all lung cancer diagnoses. The most common presenting symptoms (cough, sputum production, and chest pain) in conjunction with its radiographic findings (patchy, multi-lobar infiltrates) make invasive mucinous adenocarcinoma challenging to distinguish from both infectious and inflammatory pneumonia. However, due to its aggressive nature, invasive mucinous adenocarcinoma should be considered if a presumed case of pneumonia lacks symptoms of infection (e.g., fever, leukocytosis) and/or does not respond to antibiotics. We report the case of a 75-year-old male who was admitted in the setting of a presumed case of recurrent pneumonia, which had failed to respond to prior antibiotic therapy. Further workup, including trans-bronchial biopsy, confirmed mucinous adenocarcinoma with a lepidic pattern. This case highlights the importance of establishing a broad differential in the setting of unresolved pneumonia following appropriate antibiotic coverage.